Richard C. Pfenniger Jr.
Richard C. Pfenniger Jr.'s purchase track record
How the stock did after each of Richard C. Pfenniger Jr.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/5/2024 | OPK | $23K | +51.7% | +41.6% | +18.5% |
| 11/13/2023 | OPK | $32K | -18.8% | -1.6% | +18.4% |
| 11/8/2023 | WGS | $15K | +156.2% | pending | — |
| 8/17/2023 | WGS | $26K | -71.4% | -13.4% | +15.1% |
| 5/18/2023 | WGS | $29K | -15.0% | -75.7% | +7.4% |
| 8/20/2021 | COCP | $41K | -19.6% | -49.0% | -2.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.
Transaction History
| WGS | ▲ Buy | Option Exercise | 3,576 | $0 | 6/18/2026 | View on chart |
| FLNT | ▲ Buy | Grant | 30,096 | $0 | 6/17/2026 | View on chart |
| COCP | ▲ Buy | Grant | 20,000 | — | 10/28/2025 | View on chart |
| FLNT | ▲ Buy | Grant | 39,682 | $0 | 6/18/2025 | View on chart |
| WGS | ▲ Buy | Option Exercise | 12,924 | $0 | 6/18/2025 | View on chart |
| WGS | ▲ Buy | Option Exercise | 918 | $0 | 5/2/2025 | View on chart |
| COCP | ▲ Buy | Grant | 8,067 | — | 10/9/2024 | View on chart |
| WGS | ▲ Buy | Option Exercise | 5,828 | $0 | 6/20/2024 | View on chart |
| FLNT | ▲ Buy | Grant | 21,429 | $0 | 6/5/2024 | View on chart |
| WGS | ▲ Buy | Option Exercise | 918 | $0 | 5/2/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 13,000 | $12K | 1/5/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 12,000 | $11K | 1/5/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 5,000 | $6K | 11/13/2023 | View on chart |
| OPK | ▲ Buy | Open Market | 5,000 | $6K | 11/13/2023 | View on chart |
| OPK | ▲ Buy | Open Market | 5,000 | $6K | 11/13/2023 | View on chart |
| OPK | ▲ Buy | Open Market | 10,000 | $13K | 11/13/2023 | View on chart |
| WGS | ▲ Buy | Open Market | 10,000 | $15K | 11/8/2023 | View on chart |
| WGS | ▲ Buy | Open Market | 5,000 | $26K | 8/17/2023 | View on chart |
| FLNT | ▲ Buy | Grant | 115,385 | $0 | 6/7/2023 | View on chart |
| WGS | ▲ Buy | Open Market | 5,000 | $29K | 5/18/2023 | View on chart |
| WGS | ▲ Buy | Option Exercise | 30,303 | $0 | 5/2/2023 | View on chart |
| FLNT | ▲ Buy | Grant | 60,000 | $0 | 10/6/2022 | View on chart |
| COCP | ▲ Buy | Open Market | 40,000 | $41K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data
GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.